title: Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells.
abstract: The presence of antiphospholipid Ab is associated with increased risk of thrombosis. The monocyte-endothelial cell interaction has been suggested to play a key role at the site of vascular injury during thrombosis. Therefore, we tested the effect of anticardiolipin Abs (aCL) on the production of monocyte chemoattractant protein-1 (MCP-1) in HUVEC. We found that monoclonal aCL as well as IgG fractions from patients with antiphospholipid syndrome (APS-IgG) could induce the production of MCP-1 in HUVEC. The ability of IgG aCL to induce MCP-1 production could be abrogated by preabsorption with cardiolipin liposomes. Simultaneous addition of either monoclonal aCL or APS-IgG with IL-1beta resulted in synergistic increase in MCP-1 production, whereas the addition of control IgG lacking aCL activity did not alter IL-1beta-induced levels of MCP-1. MCP-1 mRNA expression was also up-regulated when HUVEC were incubated with either APS-IgG or monoclonal aCL, and down-regulated by the treatment of dexamethasone. In addition, we found that serum levels of MCP-1 in 76 systemic lupus erythematosus patients correlated well with the titers of IgG aCL. Collectively, these results indicate that aCL could promote endothelial cell-monocyte cross-talk by enhancing the endothelial production of MCP-1, thereby shifting the hemostatic balance toward the prothrombotic state of APS.
authors.affiliation: Department of Medicine, Division of Rheumatology, Center for Rheumatic Diseases, Kangnam St. Mary's Hospital, Catholic University of Korea, Seoul, Korea. chocs@cmc.cuk.ac.kr
authors.forename: Chul-Soo
authors.initials: CS
authors.lastname: Cho
authors.forename: Mi-La
authors.initials: ML
authors.lastname: Cho
authors.forename: Pojen P
authors.initials: PP
authors.lastname: Chen
authors.forename: So-Youn
authors.initials: SY
authors.lastname: Min
authors.forename: Sue-Yun
authors.initials: SY
authors.lastname: Hwang
authors.forename: Kyung-Soo
authors.initials: KS
authors.lastname: Park
authors.forename: Wan-Uk
authors.initials: WU
authors.lastname: Kim
authors.forename: Do-June
authors.initials: DJ
authors.lastname: Min
authors.forename: Jun-Ki
authors.initials: JK
authors.lastname: Min
authors.forename: Sung-Hwan
authors.initials: SH
authors.lastname: Park
authors.forename: Ho-Youn
authors.initials: HY
authors.lastname: Kim
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood / Q000494:pharmacology*; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000166:cytology / Q000276:immunology* / Q000378:metabolism*; D005260:Female; D006023:Glycoproteins / Q000502:physiology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology; D008297:Male; D012333:RNA, Messenger / Q000096:biosynthesis; D053482:beta 2-Glycoprotein I
chemical_list: D000276:Adjuvants, Immunologic; D017153:Antibodies, Anticardiolipin; D018932:Chemokine CCL2; D006023:Glycoproteins; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D012333:RNA, Messenger; D053482:beta 2-Glycoprotein I; D003907:Dexamethasone